2023 was off to a shockingly great start! We were thrilled to acquire Neovasc, a company with a first-of-its-kind technology to address refractory angina, and are looking forward to driving value for physicians and improving the lives of an underserved patient population. The excitement for our new peripheral product, Shockwave L6, was electrifying and has continued to make waves across the U.S. Shockwave IVL and Coronary IVL became listed by SCAI as a potential therapy option across all U.S. cath labs regardless of surgical backup status. As always, we were further confirming the efficacy and safety of Shockwave IVL across different calcium morphologies through new publications. We highlight these topics and more in our latest PulsePoint Newsletter!
Read More
Topics:
Coronary IVL,
Peripheral IVL,
IVL Technology,
Coronary Clinical Data,
Peripheral Conferences,
Peripheral Clinical Data,
SWAV News,
Shockwave C2,
Coronary Conferences,
Shockwave S4,
PulsePoint Newsletter,
Calcium Corner,
Shockwave M5 & Shockwave M5+,
Reimbursement,
Treating Different Ca++ Morphologies,
Female vs. Male Outcomes,
Empower CAD
Attending SCAI next week? Get ready, because Shockwave ain't bringing nothing but heat. Take a look at the hot topics SWAV has in store for you this year including:
Read More
Topics:
Coronary IVL,
IVL Technology,
Shockwave C2,
Coronary Conferences
After 5 years of innovating together, we’re just getting started! Join us at EuroPCR 2023 to celebrate with us 5 years of Coronary IVL and find out more about our brand-new catheter, Shockwave C2+. We will go through the results of the latest clinical studies in our Symposium and discuss the main features of the new Shockwave C2+ in our Case in Point session.
With the recent acquisition of Neovasc and their innovative Reducer™ device, we are creating new opportunities for patients and physicians in the treatment of refractory angina. Join us at the Tools & Techniques session to learn how we are working to bring these patients relief from their symptoms and hopefully improve their quality of life.
À bientôt à Paris!
Read More
Topics:
Coronary IVL,
IVL Technology,
Shockwave C2,
Coronary Conferences
2022 was another big year for Shockwave and Q4 was no exception! On Twitter, the first Shockwave L6 cases were posted by physicians who participated in its limited release and it was great to see their excitement for our new large-vessel peripheral IVL catheter launching soon in the U.S.! At VIVA ‘22, Dr. Ehrin Armstrong presented the final 1,373 patient cohort data from the Disrupt PAD III Observational Study; this larger patient data set reinforces the predictability of Shockwave IVL and its ability to consistently modify calcium across vessel beds, challenging lesions and complex patients. Additionally, international calcium experts shared their real-world experiences with the safety and efficacy of coronary IVL across different calcium morphologies, including concentric, eccentric and nodular calcium. Check out that and more in the new PulsePoint Newsletter!
Read More
Topics:
Coronary IVL,
Peripheral IVL,
IVL Technology,
Coronary Clinical Data,
Peripheral Conferences,
Peripheral Clinical Data,
SWAV News,
Shockwave C2,
Coronary Conferences,
Shockwave S4,
PulsePoint Newsletter,
Calcium Corner,
Shockwave M5 & Shockwave M5+,
Reimbursement,
Treating Different Ca++ Morphologies,
Female vs. Male Outcomes,
Empower CAD
It was smooth sailing for Shockwave this summer! Thank you to everyone who made Q3 unforgettable; but before we get cozy for the holidays, let’s reflect on the events that made the quarter one to remember. This year’s TCT was particularly momentous, as we announced the first prospective, female-only study of coronary interventions, EMPOWER CAD. We also explored tips and tricks for IVL with guide extension catheter usage with Dr. Stephan Heo and debated different approaches to modifying nodular calcium with an expert panel. Read up on the latest Shockwave IVL peer-written publications and more in the Q3 PulsePoint Newsletter.
Read More
Topics:
Coronary IVL,
Peripheral IVL,
IVL Technology,
Coronary Clinical Data,
Peripheral Conferences,
Peripheral Clinical Data,
SWAV News,
Shockwave C2,
Coronary Conferences,
Shockwave S4,
PulsePoint Newsletter,
Calcium Corner,
Shockwave M5 & Shockwave M5+,
Female vs. Male Outcomes,
Empower CAD
Did you get a chance to watch the educational symposium on nodular calcium at TCT 2022? If you missed it, we’ve got you covered!
Read More
Topics:
Coronary IVL,
IVL Technology,
Coronary Clinical Data,
Shockwave C2,
Coronary Conferences,
Treating Different Ca++ Morphologies,
Female vs. Male Outcomes
Despite often being more challenging to treat, female PCI patients are under-represented in published data, with no dedicated prospective studies performed on this population. To address this unmet need, Shockwave is launching EMPOWER CAD, the first prospective, female-only study of coronary interventions.
Read More
Topics:
Coronary IVL,
IVL Technology,
Coronary Clinical Data,
Shockwave C2,
Coronary Conferences,
Treating Different Ca++ Morphologies,
Female vs. Male Outcomes
Attending TCT in Boston in a few weeks? Want to get "wicked smart" about treating coronary calcium? Shockwave has a lot in store for you:
Read More
Topics:
Coronary IVL,
IVL Technology,
Shockwave C2,
Coronary Conferences
